ArticleClinical cancer research : an official journal of the American Association for Cancer Research2021

Efficacy and Safety of Nivolumab Plus Ipilimumab versus Sunitinib in First-line Treatment of Patients with Advanced Sarcomatoid Renal Cell Carcinoma.

Nizar M Tannir et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.